Medical Research News

Nursing

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kaira K et al. – Amrubicin is an active and well–tolerated regimen in patients with previously treated lung cancer. Amrubicin 35mg/m2 seems to achieve similar efficacy with less toxicity than amrubicin 40mg/m2 in this patient population. These results warrant further evaluation in previously treated lung cancer.

Today in Clinical Pharmacology...keeping you current

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/18/09

How do providers assess antihypertensive medication adherence in medical encounters?
Journal of General Internal Medicine, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address